{"id":816288,"date":"2025-02-21T11:21:30","date_gmt":"2025-02-21T16:21:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/"},"modified":"2025-02-21T11:21:30","modified_gmt":"2025-02-21T16:21:30","slug":"lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/","title":{"rendered":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Feb.  21, 2025  (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company\u2019s Initial Public Offering (\u201cIPO\u201d) on September 15, 2023.<\/p>\n<p>On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn\u2019s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder (\u201cMDD\u201d) to show that Navacaprant offered a statistically significant improvement in treating MDD; (ii) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (iii) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.<\/p>\n<p>When investors learned the truth, Neumora\u2019s common stock declined precipitously, injuring investors.<\/p>\n<p>If you suffered a loss of more than $100,000 in Neumora\u2019s securities, and wish to participate, or learn more, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AVqjLpMyeJZruCWKi_0lw9ryrTK04yo_opPY8XGlEBPAiM9SYf1UcMHEmVcB6ua-55hghYKIK02O3YoV9wE15m-naKuJDmL3arMxHrTJcET6JiKbusivxPsMXCg617sR\" rel=\"nofollow\" target=\"_blank\">click here<\/a>, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com).<\/p>\n<p>Any investor who wishes to serve as Lead Plaintiff must act before <strong>April 7, 2025<\/strong>.<\/p>\n<p>\n        <strong>About Lowey Dannenberg<\/strong><br \/>\n        <br \/>Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.<\/p>\n<p>\n        <strong>Contact<\/strong>:<br \/>Lowey Dannenberg P.C.<br \/>44 South Broadway, Suite 1100<br \/>White Plains, NY 10601<br \/>Tel: (914) 733-7234<br \/>Email: afarah@lowey.com<\/p>\n<p>\n        <strong>SOURCE<\/strong>: Lowey Dannenberg P.C.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjdiOGRkNjUtZWUyYy00YTczLTk0YjMtM2RkZmM5MjIyYzhiLTEyMDYwODc=\/tiny\/Lowey-Dannenberg-P-C-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company\u2019s Initial Public Offering (\u201cIPO\u201d) on September 15, 2023. On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816288","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company\u2019s Initial Public Offering (\u201cIPO\u201d) on September 15, 2023. On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase &hellip; Continue reading &quot;Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T16:21:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm\",\"datePublished\":\"2025-02-21T16:21:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/\"},\"wordCount\":402,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/\",\"name\":\"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\",\"datePublished\":\"2025-02-21T16:21:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/","og_locale":"en_US","og_type":"article","og_title":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk","og_description":"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company\u2019s Initial Public Offering (\u201cIPO\u201d) on September 15, 2023. On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase &hellip; Continue reading \"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-21T16:21:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm","datePublished":"2025-02-21T16:21:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/"},"wordCount":402,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/","name":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=","datePublished":"2025-02-21T16:21:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjU3NiM2NzYyNjY1IzIxOTQ1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-notifies-neumora-therapeutics-inc-neumora-or-the-company-nasdaq-nmra-investors-of-securities-class-action-lawsuit-and-encourages-investors-w-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (\u201cNeumora\u201d or the \u201cCompany\u201d) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816288"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816288\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}